Webcasted Industry Sessions

Session Description:

Promotional symposium initiated and funded by GSK. For Healthcare professionals only.
Adverse event reporting and Prescribing Information for GSK products mentioned can be found at the end of the programme or from a GSK representative.
At GSK, we are committed to fighting meningococcal disease. Join us for a symposium session in an interactive panel discussion with a live poll to explore the global landscape of invasive meningococcal disease (IMD) and recent outbreaks. We will discuss Brazilian experience with private childhood vaccination programs, which lay the groundwork for National Immunization Programs (NIPs), providing insights into strengthening public health systems. Next, we will explore how to extend protection as children grow preventing the second peak of meningococcal disease in adolescence. This discussion will highlight the importance of continued vaccination during this critiCal age.
Finally, we will share the implementation and adoption strategies in Switzerland and Germany after achieving NIPs for infants and adolescents. We will learn about the successes and challenges faced by these countries, offering a comprehensive view of the best practices and lessons learned.
Join our expert panel to gain deeper insights into combating meningococcal disease and practical strategies to help achieve a world free of this disease.
Bexsero (Meningococcal Group B Vaccine (rDNA, component, adsorbed)) is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B. The impact of invasive disease in different age groups as well as the variability of antigen epidemiology for group B strains in different geographical areas should be considered when vaccinating. See section 5.1 for information on protection against specific group B strains. The use of this vaccine should be in accordance with official recommendations.

Link to prescribing information for GSK products mentioned during this symposium can be found here under.  Adverse event reporting information can be found at the bottom of this webpage.
EU: https://www.ema.europa.eu/en/documents/product-information/bexsero-epar-product-information_en.pdf
UK: Bexsero Meningococcal Group B vaccine for injection in pre-filled syringe – Summary of Product Characteristics (SmPC) – (emc) | 5168

Adverse events should be reported. For Great Britain and Northern Ireland, reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline +44 0800 221 441
For other countries please access reporting information at Report a possible side effect | GSK